메뉴 건너뛰기




Volumn 15, Issue 6, 2012, Pages 327-334

Public health action in genomics is now needed beyond newborn screening

Author keywords

Cascade screening; Evidenced based recommendations; Health impact; Tier 1 genomics applications

Indexed keywords

BREAST CANCER; DISABILITY; EDUCATION; FAMILIAL CANCER; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC COUNSELING; GENOMICS; HEALTH CARE POLICY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MORBIDITY; MORTALITY; NEWBORN SCREENING; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 84870789057     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000341889     Document Type: Review
Times cited : (56)

References (31)
  • 1
    • 84870794442 scopus 로고    scopus 로고
    • GAPP Knowledge Base accessed February 29, 2012
    • GAPP Knowledge Base. http://www.hu-genavigator.net/GAPPKB/(accessed February 29, 2012).
  • 2
    • 85041650131 scopus 로고    scopus 로고
    • The National Human Genome Research Institute: Appendix 5 accessed February 29, 2012
    • The National Human Genome Research Institute: Appendix 5. The history of newborn phenylketonuria screening in the U.S. http://biotech.law.lsu.edu/ research/fed/tfgt/ap-pendix5.htm (accessed February 29, 2012).
    • The History of Newborn Phenylketonuria Screening in the U.S
  • 3
    • 84882736524 scopus 로고    scopus 로고
    • Department of Health and Human Services accessed February 29, 2012
    • Department of Health and Human Services: Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. 2011. http://www.hrsa.gov/ advisorycom-mittees/mchbadvisory/heritabledisorders/recommendedpanel/(accessed February 29, 2012).
    • (2011) Secretary's Advisory Committee on Heritable Disorders in Newborns and Children
  • 6
    • 24644456397 scopus 로고    scopus 로고
    • U.S. Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement
    • U.S. Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143: 355-361.
    • (2005) Ann Intern Med , vol.143 , pp. 355-361
  • 7
    • 84870774814 scopus 로고    scopus 로고
    • National Institute for Help and Clinical Excellence accessed February 29, 2012
    • National Institute for Help and Clinical Excellence: CG71 familial hypercholesterolae-mia: NICE guideline. 2010. http://guidance. nice.org.uk/CG71/NICEGuidance/pdf/English (accessed February 29, 2012).
    • (2010) CG71 Familial Hypercholesterolae-mia: NICE Guideline
  • 8
    • 59849108362 scopus 로고    scopus 로고
    • Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11: 35-41.
    • (2009) Genet Med , vol.11 , pp. 35-41
  • 9
    • 84870830511 scopus 로고    scopus 로고
    • accessed February 29, 2012
    • Healthy People.gov: 2020 Topics & Objectives, Genomics. 2012. http://www.healthy-people.gov/2020/topicsobjectives2020/ob-jectiveslist.aspx? topicId = 15 (accessed February 29, 2012).
    • (2012) Healthy People.gov: 2020 Topics & Objectives Genomics
  • 11
    • 0030461680 scopus 로고    scopus 로고
    • From genes to public health: The applications of genetic technology in disease prevention. Genetics Working Group
    • Khoury MJ: From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 1996; 86:1717-1722.
    • (1996) Am J Public Health , vol.86 , pp. 1717-1722
    • Khoury, M.J.1
  • 12
    • 77949444879 scopus 로고    scopus 로고
    • A framework for public health action: The health impact pyramid
    • Frieden TR: A framework for public health action: the health impact pyramid. Am J Public Health 2010; 100: 590-595.
    • (2010) Am J Public Health , vol.100 , pp. 590-595
    • Frieden, T.R.1
  • 13
    • 84857058760 scopus 로고    scopus 로고
    • Using core public health functions to promote BRCA best practices among health plans
    • Duquette D, Lew is K, McLosky J, Bach J: Using core public health functions to promote BRCA best practices among health plans. Public Health Genomics 2012; 15:92-97.
    • (2012) Public Health Genomics , vol.15 , pp. 92-97
    • Duquette, D.1    Lewis, K.2    McLosky, J.3    Bach, J.4
  • 14
    • 84870837661 scopus 로고    scopus 로고
    • accessed February 29, 2012
    • http://intranet.cdc.gov/osels/phspo/bc/bc -registry-profiles/Profile- Behavioral-Risk-Factor-Surveillance-System-BRFSS.pdf (accessed February 29, 2012).
  • 16
    • 46049089154 scopus 로고    scopus 로고
    • National Cancer Institute accessed February 29, 2012
    • National Cancer Institute: Breast Cancer. 2012. http://www.cancer.gov/ cancertopics/types/breast (accessed February 29, 2012).
    • (2012) Breast Cancer
  • 17
    • 57149130267 scopus 로고    scopus 로고
    • National Cancer Institute accessed February 29, 2012
    • National Cancer Institute: Ovarian Cancer. 2012. http://www.cancer.gov/ cancertopics/types/ovarian (accessed February 29, 2012).
    • (2012) Ovarian Cancer
  • 18
    • 78649996861 scopus 로고    scopus 로고
    • National Cancer Institute accessed February 29, 2012
    • National Cancer Institute: BRCA1 and BRCA2: Cancer Risk and Genetic Testing. 2009. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA #r4 (accessed February 29, 2012).
    • (2009) BRCA1 and BRCA2: Cancer Risk and Genetic Testing.
  • 19
    • 33646537461 scopus 로고    scopus 로고
    • Disparities in genetic testing: Thinking outside the BRCA box
    • Hall MJ, Olopade OI: Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006; 24:2197-2203.
    • (2006) J Clin Oncol , vol.24 , pp. 2197-2203
    • Hall, M.J.1    Olopade, O.I.2
  • 20
    • 78650844345 scopus 로고    scopus 로고
    • The search for unaffected individuals with Lynch syndrome: Do the ends justify the means?
    • Hampel H, de la Chapelle A: The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila) 2011; 4:1-5.
    • (2011) Cancer Prev Res (Phila) , vol.4 , pp. 1-5
    • Hampel, H.1    De La Chapelle, A.2
  • 21
    • 77149122082 scopus 로고    scopus 로고
    • The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
    • Mvundura M, Grosse SD, Hampel H, Palo-maki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12:93-104.
    • (2010) Genet Med , vol.12 , pp. 93-104
    • Mvundura, M.1    Grosse, S.D.2    Hampel, H.3    Palo-Maki, G.E.4
  • 22
    • 84857619617 scopus 로고    scopus 로고
    • Cascade screening for familial hypercholesterolemia (FH)
    • Ned RM, Sijbrands EJ: Cascade screening for familial hypercholesterolemia (FH). PLoS Curr 2011; 3:RRN1238.
    • (2011) PLoS Curr , vol.3
    • Ned, R.M.1    Sijbrands, E.J.2
  • 23
    • 0025944056 scopus 로고
    • Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group
    • Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303: 893-896.
    • (1991) BMJ , vol.303 , pp. 893-896
  • 24
    • 12244262220 scopus 로고    scopus 로고
    • Family history assessment: Strategies for prevention of cardiovascular disease
    • Hunt SC, Gwinn M, Adams T: Family history assessment: strategies for prevention of cardiovascular disease. Am J Prev Med 2003; 24: 136-142.
    • (2003) Am J Prev Med , vol.24 , pp. 136-142
    • Hunt, S.C.1    Gwinn, M.2    Adams, T.3
  • 25
    • 79953230423 scopus 로고    scopus 로고
    • Prevention of intellectual disability through screening for congenital hypothyroidism: How much and at what level?
    • Grosse SD, Van Vliet G: Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level? Arch Dis Child 2011; 96: 374-379.
    • (2011) Arch Dis Child , vol.96 , pp. 374-379
    • Grosse, S.D.1    Van Vliet, G.2
  • 26
    • 1342269036 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention: Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment-United States, 2003
    • Centers for Disease Control and Prevention: Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment-United States, 2003. MMWR Morb Morta l Wkly Rep 2004; 53: 57-59.
    • (2004) MMWR Morb Morta L Wkly Rep , vol.53 , pp. 57-59
  • 27
    • 77954275935 scopus 로고    scopus 로고
    • How much does IQ raise earnings? Implications for regulatory impact analyses
    • Grosse SD: How much does IQ raise earnings? Implications for regulatory impact analyses. AERE NL 2007; 27:17-21.
    • (2007) AERE NL , vol.27 , pp. 17-21
    • Grosse, S.D.1
  • 28
    • 57849158453 scopus 로고    scopus 로고
    • Education cost savings from early detection of hearing loss: New findings
    • Grosse SD: Education cost savings from early detection of hearing loss: new findings. Volta V 2007; 14:38-40.
    • (2007) Volta v , vol.14 , pp. 38-40
    • Grosse, S.D.1
  • 29
    • 0033997009 scopus 로고    scopus 로고
    • The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: A decision analysis
    • Tengs TO, Berry DA: The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Dis Manage Clin Outcomes 2000; 2:15-24.
    • (2000) Dis Manage Clin Outcomes , vol.2 , pp. 15-24
    • Tengs, T.O.1    Berry, D.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.